# Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer

> **NCT06727214** · — · NOT_YET_RECRUITING · sponsor: **Sara Mahmoud Ahmed Mahmoud** · enrollment: 87 (estimated)

## Conditions studied

- Bladder Urothelial Carcinoma

## Interventions

- **DRUG:** Chemotherapy with platine

## Key facts

- **NCT ID:** NCT06727214
- **Lead sponsor:** Sara Mahmoud Ahmed Mahmoud
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-04
- **Primary completion:** 2026-11-04
- **Final completion:** 2026-12-01
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06727214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06727214, "Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06727214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*